When a first-in-class therapy launches, patients, clinicians, and payers start talking before field engagement begins. Here's what Medical Affairs can learn by monitoring in real time.
Author(s): Akansha Kumar
Key Takeaways
- First-in-class launches generate multi-directional conversation immediately after approval. Patients, clinicians, payers, and advocacy groups do not wait for formal field engagement to begin.
- Cost and access information, including out-of-pocket costs and assistance-program experiences, circulates publicly and influences how other patients interpret a new therapy.
- Clinicians are looking for real-world evidence across diverse patient types before broad adoption. Clinical trial data is a starting point, not the endpoint.
- Sentiment can shift in weeks, not quarters. By the time field feedback arrives, the online conversation has often already moved.
- Medical Science Liaisons who monitor these conversations before their first in-person engagement enter with better preparation than those who do not.
